Selection for advanced NSCLC treatment with erlotinib may be guided by identification of tumor biomarkers that predict clinical benefit. Annals of Oncology
Dr. Mark Kris underscores the importance of testing for EGFR mutations in patients with non-small cell lung cancer, as evidenced by recent ASCOŽ presentations. br / iMedscape Hematology-Oncology/i
Dr. John Marshall probes critical issues in fighting a smarter war against cancer, issues that will be addressed by all stakeholders in cancer care during a symposium in Washington, DC, December 1-3. Medscape Hematology-Oncology
A study shows that factors such as age at menopause and breast-feeding practices may influence the risk for the development of certain types of breast cancer. Medscape Medical News
